Inventiva (FRA:6IV) EBIT : €-95.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inventiva EBIT?

Inventiva's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was €-43.69 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was €-95.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Inventiva's annualized ROC % for the quarter that ended in Jun. 2024 was -484.58%. Inventiva's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -1,021.64%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Inventiva's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -57.14%.

Inventiva EBIT Historical Data

The historical data trend for Inventiva's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inventiva EBIT Chart

Inventiva Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-30.21

-33.55

-49.14

-53.59

-104.64

Inventiva Semi-Annual Data
	Dec13	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial															-29.24	-24.35	-53.33	-51.31	-43.69

Competitive Comparison of Inventiva's EBIT

For the Biotechnology subindustry, Inventiva's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inventiva's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inventiva's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Inventiva's EV-to-EBIT falls into.

Inventiva EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-95.00 Mil.

Inventiva (FRA:6IV) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Inventiva's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-104.498 * ( 1 - -0.24% )	/	( (26.686	+	16.547)	/ 2 )
=	-104.7487952	/	21.6165
=	-484.58 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	69.561	-	44.844	-	( 26.988	-	max(0, 50.158	-	48.189	+	26.988	))
=	26.686

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	39.426	-	42.417	-	( 10.147	-	max(0, 48.146	-	28.608	+	10.147	))
=	16.547

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Inventiva's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-87.386	/	( ( (9.127 + max(-35.549, 0))	+	(7.98 + max(-33.89, 0)) )	/	2 )
=	-87.386	/	( ( 9.127	+	7.98 )	/	2 )
=	-87.386	/	8.5535
=	-1,021.64 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.807	+	0.417	+	5.077)	-	(44.844	+	0.006	+	0)
=	-35.549

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.809	+	0.393	+	7.328)	-	(42.417	+	0.003	+	0)
=	-33.89

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Inventiva's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-94.999	/	166.259
	=	-57.14 %

Inventiva EBIT Related Terms

Thank you for viewing the detailed overview of Inventiva's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Inventiva Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (FRA:6IV) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

IVA:USA 0RNK:UK IVA:France

Address

50 rue de Dijon, Daix, FRA, 21121

Website

https://www.inventivapharma.com

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Inventiva Headlines

No Headlines